Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 16/2023

20.08.2023 | Research

Profile and clinical significance of interferon gamma-inducible protein-10 (IP-10) and its receptor in patients with hepatocellular carcinoma

verfasst von: Yongtao Li, Chengfei Wang, Xuying Yin, Lili Jiang, Xuefen Li, Jiezuan Yang

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 16/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

Chemokines play a vital role in tumor progression, metastasis and prognosis; however, the profile and clinical significance of gamma interferon-inducible protein-10 (IP-10) and its receptor (CXCR3) in patients with hepatocellular carcinoma (HCC) have not been well evaluated.

Methods

Liquid-phase chip technology was used to detect the serum IP-10 in 85 patients with HBV-related HCC, 50 patients with chronic hepatitis B (CHB) and 50 liver cirrhosis subjects (CS); simultaneously, the CXCR3 and Alpha fetoprotein (AFP) were determined. Additionally, their mRNA or protein expression levels in peripheral blood mononuclear cells (PBMC), liver tumor and paracancerous tissues were quantified using qRT-PCR or ELISA. Moreover, the IP-10 and CXCR3 expression was verified by the online data from Gene Expression Omnibus. Furthermore, the relationships of serum IP-10, CXCR3 and AFP levels with their overall survival rate were also analyzed.

Results

The levels of IP-10 and CXCR3 in HCC group were significantly higher than those in CHB and CS groups, and their mRNA of PBMC is significantly positive correlation with those in their liver tissues or HBV DNA load (P < 0.0001), respectively. The serum IP-10 and CXCR3 in HCC were significantly correlated with tumor differentiation, metastases staging and distant metastasis (P < 0.05), but not related to gender, age and tumor size (P > 0.05, except IP-10 based on age).

Conclusions

The serum IP-10 (142.6 pg/mL) and CXCR3 (241.2 pg/mL) could be differential diagnostic surrogates that distinguish HCC from CS, and the lower IP-10 level may be conducive to the postoperative survival of HCC patients. Moreover, the IP-10 and CXCR3 would be related to anti-tumor immunity in HCC patients and be a potential target for treatment of HCC.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
Zurück zum Zitat Britton C, Poznansky MC, Reeves P (2021) Polyfunctionality of the CXCR4/CXCL12 axis in health and disease: implications for therapeutic interventions in cancer and immune-mediated diseases. FASEB J 35:e21260CrossRefPubMed Britton C, Poznansky MC, Reeves P (2021) Polyfunctionality of the CXCR4/CXCL12 axis in health and disease: implications for therapeutic interventions in cancer and immune-mediated diseases. FASEB J 35:e21260CrossRefPubMed
Zurück zum Zitat Chen VL, Sharma P (2020) Role of biomarkers and biopsy in hepatocellular carcinoma. Clin Liver Dis 24:577–590CrossRefPubMed Chen VL, Sharma P (2020) Role of biomarkers and biopsy in hepatocellular carcinoma. Clin Liver Dis 24:577–590CrossRefPubMed
Zurück zum Zitat Clark AM, Heusey HL, Griffith LG, Lauffenburger DA, Wells A (2021) IP-10 (CXCL10) can trigger emergence of dormant breast cancer cells in a metastatic liver microenvironment. Front Oncol 11:676135CrossRefPubMedPubMedCentral Clark AM, Heusey HL, Griffith LG, Lauffenburger DA, Wells A (2021) IP-10 (CXCL10) can trigger emergence of dormant breast cancer cells in a metastatic liver microenvironment. Front Oncol 11:676135CrossRefPubMedPubMedCentral
Zurück zum Zitat Cong WM, Bu H, Chen J, Dong H, Zhu YY, Feng LH, Chen J (2016) Practice guidelines for the pathological diagnosis of primary liver cancer: 2015 update. World J Gastroenterol 22:9279–9287CrossRefPubMedPubMedCentral Cong WM, Bu H, Chen J, Dong H, Zhu YY, Feng LH, Chen J (2016) Practice guidelines for the pathological diagnosis of primary liver cancer: 2015 update. World J Gastroenterol 22:9279–9287CrossRefPubMedPubMedCentral
Zurück zum Zitat Elia G, Fallahi P (2017) Hepatocellular carcinoma and CXCR3 chemokines: a narrative review. Clin Ter 168:e37–e41PubMed Elia G, Fallahi P (2017) Hepatocellular carcinoma and CXCR3 chemokines: a narrative review. Clin Ter 168:e37–e41PubMed
Zurück zum Zitat Fasano R, Shadbad MA, Brunetti O, Argentiero A, Calabrese A, Nardulli P, Calbi R, Baradaran B, Silvestris N (2021) Immunotherapy for hepatocellular carcinoma: new prospects for the cancer therapy. Life (basel, Switzerland) 11:1355PubMed Fasano R, Shadbad MA, Brunetti O, Argentiero A, Calabrese A, Nardulli P, Calbi R, Baradaran B, Silvestris N (2021) Immunotherapy for hepatocellular carcinoma: new prospects for the cancer therapy. Life (basel, Switzerland) 11:1355PubMed
Zurück zum Zitat Groover MK, Richmond JM (2020) Potential therapeutic manipulations of the CXCR3 chemokine axis for the treatment of inflammatory fibrosing diseases. F1000Res 9:1197CrossRefPubMedPubMedCentral Groover MK, Richmond JM (2020) Potential therapeutic manipulations of the CXCR3 chemokine axis for the treatment of inflammatory fibrosing diseases. F1000Res 9:1197CrossRefPubMedPubMedCentral
Zurück zum Zitat Guo R, Mao H, Hu X, Zheng N, Yan D, He J, Yang J (2016) Slow reduction of IP-10 Levels predicts HBeAg seroconversion in chronic hepatitis B patients with 5 years of entecavir treatment. Sci Rep 6:37015CrossRefPubMedPubMedCentral Guo R, Mao H, Hu X, Zheng N, Yan D, He J, Yang J (2016) Slow reduction of IP-10 Levels predicts HBeAg seroconversion in chronic hepatitis B patients with 5 years of entecavir treatment. Sci Rep 6:37015CrossRefPubMedPubMedCentral
Zurück zum Zitat Hueso L, Ortega R, Selles F, Wu-Xiong NY, Ortega J, Civera M, Ascaso JF, Sanz MJ, Real JT, Piqueras L (2018) Upregulation of angiostatic chemokines IP-10/CXCL10 and I-TAC/CXCL11 in human obesity and their implication for adipose tissue angiogenesis. Int J Obes 2005(42):1406–1417CrossRef Hueso L, Ortega R, Selles F, Wu-Xiong NY, Ortega J, Civera M, Ascaso JF, Sanz MJ, Real JT, Piqueras L (2018) Upregulation of angiostatic chemokines IP-10/CXCL10 and I-TAC/CXCL11 in human obesity and their implication for adipose tissue angiogenesis. Int J Obes 2005(42):1406–1417CrossRef
Zurück zum Zitat Jia L, Gao Y, He Y, Hooper JD, Yang P (2020) HBV induced hepatocellular carcinoma and related potential immunotherapy. Pharmacol Res 159:104992CrossRefPubMed Jia L, Gao Y, He Y, Hooper JD, Yang P (2020) HBV induced hepatocellular carcinoma and related potential immunotherapy. Pharmacol Res 159:104992CrossRefPubMed
Zurück zum Zitat Lei Y, Xu X, Liu H, Chen L, Zhou H, Jiang J, Yang Y, Wu B (2021) HBx induces hepatocellular carcinogenesis through ARRB1-mediated autophagy to drive the G(1)/S cycle. Autophagy 17:4423–4441CrossRefPubMedPubMedCentral Lei Y, Xu X, Liu H, Chen L, Zhou H, Jiang J, Yang Y, Wu B (2021) HBx induces hepatocellular carcinogenesis through ARRB1-mediated autophagy to drive the G(1)/S cycle. Autophagy 17:4423–4441CrossRefPubMedPubMedCentral
Zurück zum Zitat Levrero M, Zucman-Rossi J (2016) Mechanisms of HBV-induced hepatocellular carcinoma. J Hepatol 64:S84-s101CrossRefPubMed Levrero M, Zucman-Rossi J (2016) Mechanisms of HBV-induced hepatocellular carcinoma. J Hepatol 64:S84-s101CrossRefPubMed
Zurück zum Zitat Li CX, Ling CC, Shao Y, Xu A, Li XC, Ng KT, Liu XB, Ma YY, Qi X, Liu H, Liu J, Yeung OW, Yang XX, Liu QS, Lam YF, Zhai Y, Lo CM, Man K (2016) CXCL10/CXCR3 signaling mobilized-regulatory T cells promote liver tumor recurrence after transplantation. J Hepatol 65:944–952CrossRefPubMed Li CX, Ling CC, Shao Y, Xu A, Li XC, Ng KT, Liu XB, Ma YY, Qi X, Liu H, Liu J, Yeung OW, Yang XX, Liu QS, Lam YF, Zhai Y, Lo CM, Man K (2016) CXCL10/CXCR3 signaling mobilized-regulatory T cells promote liver tumor recurrence after transplantation. J Hepatol 65:944–952CrossRefPubMed
Zurück zum Zitat Li L, Zhu YH, Li Y, Guan XY (2017) Identification of chemokine CXCL10 in tumor microenvironment by antibody array as a prognostic marker in hepatocellular carcinoma. Neoplasma 64:778–786CrossRefPubMed Li L, Zhu YH, Li Y, Guan XY (2017) Identification of chemokine CXCL10 in tumor microenvironment by antibody array as a prognostic marker in hepatocellular carcinoma. Neoplasma 64:778–786CrossRefPubMed
Zurück zum Zitat Li M, Chen L, Gao Y, Li M, Wang X, Qiang L, Wang X (2020) Recent advances targeting C-C chemokine receptor type 2 for liver diseases in monocyte/macrophage. Liver Int J 40:2928–2936CrossRef Li M, Chen L, Gao Y, Li M, Wang X, Qiang L, Wang X (2020) Recent advances targeting C-C chemokine receptor type 2 for liver diseases in monocyte/macrophage. Liver Int J 40:2928–2936CrossRef
Zurück zum Zitat Ozga AJ, Chow MT, Lopes ME, Servis RL, Di Pilato M, Dehio P, Lian J, Mempel TR, Luster AD (2022) CXCL10 chemokine regulates heterogeneity of the CD8(+) T cell response and viral set point during chronic infection. Immunity 55:82-97.e88CrossRefPubMed Ozga AJ, Chow MT, Lopes ME, Servis RL, Di Pilato M, Dehio P, Lian J, Mempel TR, Luster AD (2022) CXCL10 chemokine regulates heterogeneity of the CD8(+) T cell response and viral set point during chronic infection. Immunity 55:82-97.e88CrossRefPubMed
Zurück zum Zitat Pan M, Wei X, Xiang X, Liu Y, Zhou Q, Yang W (2023) Targeting CXCL9/10/11-CXCR3 axis: an important component of tumor-promoting and antitumor immunity. Clin Transl Oncol 25:2306–2320CrossRefPubMed Pan M, Wei X, Xiang X, Liu Y, Zhou Q, Yang W (2023) Targeting CXCL9/10/11-CXCR3 axis: an important component of tumor-promoting and antitumor immunity. Clin Transl Oncol 25:2306–2320CrossRefPubMed
Zurück zum Zitat Petty AJ, Li A, Wang X, Dai R, Heyman B, Hsu D, Huang X, Yang Y (2019) Hedgehog signaling promotes tumor-associated macrophage polarization to suppress intratumoral CD8+ T cell recruitment. J Clin Invest 129:5151–5162CrossRefPubMedPubMedCentral Petty AJ, Li A, Wang X, Dai R, Heyman B, Hsu D, Huang X, Yang Y (2019) Hedgehog signaling promotes tumor-associated macrophage polarization to suppress intratumoral CD8+ T cell recruitment. J Clin Invest 129:5151–5162CrossRefPubMedPubMedCentral
Zurück zum Zitat Ren T, Zhu L, Cheng M (2017) CXCL10 accelerates EMT and metastasis by MMP-2 in hepatocellular carcinoma. Am J Transl Res 9:2824–2837PubMedPubMedCentral Ren T, Zhu L, Cheng M (2017) CXCL10 accelerates EMT and metastasis by MMP-2 in hepatocellular carcinoma. Am J Transl Res 9:2824–2837PubMedPubMedCentral
Zurück zum Zitat Sagnelli E, Macera M, Russo A, Coppola N, Sagnelli C (2020) Epidemiological and etiological variations in hepatocellular carcinoma. Infection 48:7–17CrossRefPubMed Sagnelli E, Macera M, Russo A, Coppola N, Sagnelli C (2020) Epidemiological and etiological variations in hepatocellular carcinoma. Infection 48:7–17CrossRefPubMed
Zurück zum Zitat Salarnia F, Behboudi E, Shahramian I, Moradi A (2021) Novel X gene point mutations in chronic hepatitis B and HBV related cirrhotic patients. Infect Genet Evol 97:105186CrossRefPubMed Salarnia F, Behboudi E, Shahramian I, Moradi A (2021) Novel X gene point mutations in chronic hepatitis B and HBV related cirrhotic patients. Infect Genet Evol 97:105186CrossRefPubMed
Zurück zum Zitat Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HLY, Chen CJ, Chen DS, Chen HL, Chen PJ, Chien RN, Dokmeci AK, Gane E, Hou JL, Jafri W, Jia J, Kim JH, Lai CL, Lee HC, Lim SG, Liu CJ, Locarnini S, Al Mahtab M, Mohamed R, Omata M, Park J, Piratvisuth T, Sharma BC, Sollano J, Wang FS, Wei L, Yuen MF, Zheng SS, Kao JH (2016) Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 10:1–98CrossRefPubMed Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HLY, Chen CJ, Chen DS, Chen HL, Chen PJ, Chien RN, Dokmeci AK, Gane E, Hou JL, Jafri W, Jia J, Kim JH, Lai CL, Lee HC, Lim SG, Liu CJ, Locarnini S, Al Mahtab M, Mohamed R, Omata M, Park J, Piratvisuth T, Sharma BC, Sollano J, Wang FS, Wei L, Yuen MF, Zheng SS, Kao JH (2016) Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 10:1–98CrossRefPubMed
Zurück zum Zitat Sartorius K, Swadling L, An P, Makarova J, Winkler C, Chuturgoon A, Kramvis A (2020) The multiple roles of hepatitis B virus X protein (HBx) dysregulated MicroRNA in hepatitis B virus-associated hepatocellular carcinoma (HBV-HCC) and immune pathways. Viruses 12:746CrossRefPubMedPubMedCentral Sartorius K, Swadling L, An P, Makarova J, Winkler C, Chuturgoon A, Kramvis A (2020) The multiple roles of hepatitis B virus X protein (HBx) dysregulated MicroRNA in hepatitis B virus-associated hepatocellular carcinoma (HBV-HCC) and immune pathways. Viruses 12:746CrossRefPubMedPubMedCentral
Zurück zum Zitat Sekiba K, Otsuka M, Koike K (2021) Potential of HBx gene for hepatocarcinogenesis in noncirrhotic liver. Semin Liver Dis 41:142–149CrossRefPubMed Sekiba K, Otsuka M, Koike K (2021) Potential of HBx gene for hepatocarcinogenesis in noncirrhotic liver. Semin Liver Dis 41:142–149CrossRefPubMed
Zurück zum Zitat Shang X, Wang L, Liu Y, Liu X, Lv J, Zhou X, Wang H, Nazierhan S, Wang J, Ma X (2021) Diagnostic value of CXCR3 and its ligands in spinal tuberculosis. Exp Ther Med 21:73CrossRefPubMed Shang X, Wang L, Liu Y, Liu X, Lv J, Zhou X, Wang H, Nazierhan S, Wang J, Ma X (2021) Diagnostic value of CXCR3 and its ligands in spinal tuberculosis. Exp Ther Med 21:73CrossRefPubMed
Zurück zum Zitat Tokunaga R, Zhang W, Naseem M, Puccini A, Berger MD, Soni S, McSkane M, Baba H, Lenz HJ (2018) CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation—a target for novel cancer therapy. Cancer Treat Rev 63:40–47CrossRefPubMed Tokunaga R, Zhang W, Naseem M, Puccini A, Berger MD, Soni S, McSkane M, Baba H, Lenz HJ (2018) CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation—a target for novel cancer therapy. Cancer Treat Rev 63:40–47CrossRefPubMed
Zurück zum Zitat Tsai CF, Chen JH, Yeh WL (2019) Pulmonary fibroblasts-secreted CXCL10 polarizes alveolar macrophages under pro-inflammatory stimuli. Toxicol Appl Pharmacol 380:114698CrossRefPubMed Tsai CF, Chen JH, Yeh WL (2019) Pulmonary fibroblasts-secreted CXCL10 polarizes alveolar macrophages under pro-inflammatory stimuli. Toxicol Appl Pharmacol 380:114698CrossRefPubMed
Zurück zum Zitat Wang Q, Cheng ST, Chen J (2020) HBx mediated increase of SIRT1 contributes to HBV-related hepatocellular carcinoma tumorigenesis. Int J Med Sci 17:1783–1794CrossRefPubMedPubMedCentral Wang Q, Cheng ST, Chen J (2020) HBx mediated increase of SIRT1 contributes to HBV-related hepatocellular carcinoma tumorigenesis. Int J Med Sci 17:1783–1794CrossRefPubMedPubMedCentral
Zurück zum Zitat Wungu CDK, Ariyanto FC, Prabowo GI, Handajani R (2020) Association between five types of Tumor Necrosis Factor-α gene polymorphism and hepatocellular carcinoma risk: a meta-analysis. BMC Cancer 20:1134CrossRefPubMedPubMedCentral Wungu CDK, Ariyanto FC, Prabowo GI, Handajani R (2020) Association between five types of Tumor Necrosis Factor-α gene polymorphism and hepatocellular carcinoma risk: a meta-analysis. BMC Cancer 20:1134CrossRefPubMedPubMedCentral
Zurück zum Zitat Xie L, Yin J, Xia R, Zhuang G (2018) Cost-effectiveness of antiviral treatment after resection in hepatitis B virus-related hepatocellular carcinoma patients with compensated cirrhosis. Hepatology 68:1476–1486CrossRefPubMed Xie L, Yin J, Xia R, Zhuang G (2018) Cost-effectiveness of antiviral treatment after resection in hepatitis B virus-related hepatocellular carcinoma patients with compensated cirrhosis. Hepatology 68:1476–1486CrossRefPubMed
Zurück zum Zitat Yan Y, Zheng L, Du Q, Yazdani H, Dong K, Guo Y, Geller DA (2021) Interferon regulatory factor 1(IRF-1) activates anti-tumor immunity via CXCL10/CXCR3 axis in hepatocellular carcinoma (HCC). Cancer Lett 506:95–106CrossRefPubMedPubMedCentral Yan Y, Zheng L, Du Q, Yazdani H, Dong K, Guo Y, Geller DA (2021) Interferon regulatory factor 1(IRF-1) activates anti-tumor immunity via CXCL10/CXCR3 axis in hepatocellular carcinoma (HCC). Cancer Lett 506:95–106CrossRefPubMedPubMedCentral
Zurück zum Zitat Zhang Y, Zhao W, Li S, Lv M, Yang X, Li M, Zhang Z (2019) CXCL11 promotes self-renewal and tumorigenicity of α2δ1(+) liver tumor-initiating cells through CXCR3/ERK1/2 signaling. Cancer Lett 449:163–171CrossRefPubMed Zhang Y, Zhao W, Li S, Lv M, Yang X, Li M, Zhang Z (2019) CXCL11 promotes self-renewal and tumorigenicity of α2δ1(+) liver tumor-initiating cells through CXCR3/ERK1/2 signaling. Cancer Lett 449:163–171CrossRefPubMed
Zurück zum Zitat Zhou H, Wu J, Wang T, Zhang X, Liu D (2016) CXCL10/CXCR3 axis promotes the invasion of gastric cancer via PI3K/AKT pathway-dependent MMPs production. Biomed Pharmacother 82:479–488CrossRefPubMed Zhou H, Wu J, Wang T, Zhang X, Liu D (2016) CXCL10/CXCR3 axis promotes the invasion of gastric cancer via PI3K/AKT pathway-dependent MMPs production. Biomed Pharmacother 82:479–488CrossRefPubMed
Metadaten
Titel
Profile and clinical significance of interferon gamma-inducible protein-10 (IP-10) and its receptor in patients with hepatocellular carcinoma
verfasst von
Yongtao Li
Chengfei Wang
Xuying Yin
Lili Jiang
Xuefen Li
Jiezuan Yang
Publikationsdatum
20.08.2023
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 16/2023
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-023-05265-1

Weitere Artikel der Ausgabe 16/2023

Journal of Cancer Research and Clinical Oncology 16/2023 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.